心外膜脂肪组织厚度对2型糖尿病患者发生慢性心力衰竭的预测价值

doi:10.3969/j.issn.1671-7171.2026.08.012

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1211 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the predictive value of epicardial adipose tissue (EAT) thickness for chronic heart failure (CHF) in patients with type 2 diabetes mellitus (T2DM). 【Methods】 The clinical data of 120 patients with T2DM admitted to Anyang People's Hospital from May 2022 to May 2024 were retrospectively analyzed. Among them, 52 patients who developed CHF during follow-up were assigned to the observation group, and 68 patients without CHF were assigned to the control group. Glucose metabolic indicators [fasting plasma glucose (FPG), 2-hour postprandial plasma glucose (2hPG), glycated hemoglobin (HbA1c), fasting insulin (FINS)], EAT thickness and coronary artery disease burden (Gensini score) were compared between the two groups. Logistic regression was used to analyze the influencing factors for CHF in T2DM patients, and receiver operating characteristic (ROC) curve was adopted to evaluate the clinical predictive value of EAT thickness for CHF in T2DM patients. 【Results】 The levels of FPG, 2hPG and HbA1c in the observation group were higher, while FINS level was lower than those in the control group (all P<0.05). EAT thickness and Gensini score in the observation group were higher than those in the control group (all P<0.05). Logistic regression analysis demonstrated that FPG, FINS, EAT thickness and Gensini score were influencing factors for CHF in T2DM patients (all P<0.05). ROC curve analysis showed that the area under the curve of EAT thickness for predicting CHF in T2DM patients was 0.895 (95%CI:0.600-0.823), with a sensitivity of 88.76%, specificity of 88.24% and Youden index of 0.670. 【Conclusion】 EAT thickness presents favorable predictive value for CHF in T2DM patients and can be applied for clinical risk assessment.

Key words： Diabetes Mellitus, Type 2 Heart Failure Adipose Tissue Epicardium

Received: 06 November 2025

PACS:

R587.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Zhenyu

Cite this article:

YANG Zhenyu. Predictive Value of Epicardial Adipose Tissue Thickness for Chronic Heart Failure in Patients with Type 2 Diabetes Mellitus[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(8): 1276-1278.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.08.012 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I8/1276

[1] 屈艾彬, 温馥源, 黄鑫, 等. 1990—2021年全球背景下中国2型糖尿病流行情况、疾病负担和危险因素分析及预测研究[J]. 中华流行病学杂志, 2025, 46(9): 1570-1579.
[2] Katta N, Loethen T, Lavie C J, et al. Obesity and Coronary Heart Disease: Epidemiology, Pathology, and Coronary Artery Imaging[J]. Curr Probl Cardiol,2021,46(3):100655.
[3] Wirtz P H, von Känel R. Psychological Stress, Inflammation, and Coronary Heart Disease[J]. Curr Cardiol Rep,2017,19(11):111.
[4] Einarson T R, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007—2017[J]. Cardiovasc Diabetol,2018,17(1):83.
[5] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018,38(4) :292-344.
[6] 中华医学会心血管病学分会, 中国心肌炎心肌病协作组. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789.
[7] Sunil B, Ashraf A P. Dyslipidemia in pediatric type 2 diabetes mellitus[J]. Curr Diab Rep, 2020,20(10):53.
[8] Khosla S, Samakkarnthai P, Monroe D G, et al. Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus[J]. Nat Rev Endocrinol,2021,17(11):685-697.
[9] Salgaço M K, Oliveira L G S, Costa G N, et al. Relationship between gut microbiota, probiotics, and type 2 diabetes mellitus[J]. Appl Microbiol Biotechnol,2019,103(23/24):9229-9238.
[10] 彭文超,谢严攸,史少婷,等. 心外膜脂肪组织在心血管疾病中的研究进展[J]. 临床心血管病杂志,2025,41(10):766-771.
[11] 张瑶,王鑫,王鹏, 等. 心外膜脂肪组织在心力衰竭中的研究进展[J]. 心血管病学进展,2023, 44(11):1014-1018.
[12] Jiang Q, Li J T, Sun P, et al. Effects of lifestyle interventions on glucose regulation and diabetes risk in adults with impaired glucose tolerance or prediabetes: a meta-analysis[J]. Arch Endocrinol Metab,2022,66(2):157-167.
[13] Yahagi N. Fingertip screen using POCT,HbAlc analyzer at community pharmacies is effective for early recognition of diabetes[J]. Rinsho Byori,2016,64(5):564-566.
[14] Tanaka M. Fins into limbs: Autopod acquisition and anterior elements reduction by modifying gene networks involving 5'Hox, Gli3, and Shh[J]. Dev Biol,2016,413(1):1-7.
[15] Filippatos G, Anker S D, Agarwal R, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial[J]. Circulation,2022,145(6):437-447.
[16] Taylor S I, Yazdi Z S, Beitelshees A L. Pharmacological treatment of hyperglycemia in type 2 diabetes[J]. J Clin Invest,2021,131(2):e142243.